» Articles » PMID: 36113977

Mass Cytometry-based Peripheral Blood Analysis As a Novel Tool for Early Detection of Solid Tumours: a Multicentre Study

Abstract

Objective: Early detection of a tumour remains an unmet medical need, and approaches with high sensitivity and specificity are urgently required. Mass cytometry time-of-flight (CyTOF) is a powerful technique to profile immune cells and could be applied to tumour detection. We attempted to establish diagnostic models for hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC).

Design: We performed CyTOF analysis for 2348 participants from 15 centres, including 1131 participants with hepatic diseases, 584 participants with pancreatic diseases and 633 healthy volunteers. Diagnostic models were constructed through random forest algorithm and validated in subgroups.

Results: We determined the disturbance of systemic immunity caused by HCC and PDAC, and calculated a peripheral blood immune score (PBIScore) based on the constructed model. The PBIScore exhibited good performance in detecting HCC and PDAC, with both sensitivity and specificity being around 80% in the validation cohorts. We further established an integrated PBIScore (iPBIScore) by combining PBIScore and alpha-fetoprotein or carbohydrate antigen 19-9. The iPBIScore for HCC had an area under the curve (AUC) of 0.99, 0.97 and 0.96 in training, internal validation and external validation cohorts, respectively. Similarly, the iPBIScore for PDAC showed an AUC of 0.99, 0.98 and 0.97 in the training, internal validation and external validation cohorts, respectively. In early-stage and tumour-marker-negative patients, our iPBIScore-based models also showed an AUC of 0.95-0.96 and 0.81-0.92, respectively.

Conclusion: Our study proved that the alterations of peripheral immune cell subsets could assist tumour detection, and provide a ready-to-use detection model for HCC and PDAC.

Citing Articles

Immune Cell Profiling Reveals a Common Pattern in Premetastatic Niche Formation Across Various Cancer Types.

Sugiyama S, Yumimoto K, Nakayama K Cancer Med. 2024; 14(1):e70557.

PMID: 39740041 PMC: 11683674. DOI: 10.1002/cam4.70557.


Development of machine-learning-driven signatures for diagnosing and monitoring therapeutic response in major depressive disorder using integrated immune cell profiles and plasma cytokines.

He S, Zhao F, Sun G, Shi Y, Xu T, Zhang Y Theranostics. 2024; 14(18):7265-7280.

PMID: 39629120 PMC: 11610142. DOI: 10.7150/thno.102602.


Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials.

Huang S, Jiang W, Xu S, Zhang Y, Du J, Wang Y Signal Transduct Target Ther. 2024; 9(1):285.

PMID: 39438442 PMC: 11496634. DOI: 10.1038/s41392-024-01988-w.


Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial.

Mo H, Yu Y, Sun X, Ge H, Yu L, Guan X Nat Med. 2024; 30(9):2528-2539.

PMID: 38969879 DOI: 10.1038/s41591-024-03088-2.


CD161CD127CD8 T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus.

Qu J, Li Y, Wu B, Shen Q, Chen L, Sun W Oncoimmunology. 2024; 13(1):2371575.

PMID: 38952673 PMC: 11216103. DOI: 10.1080/2162402X.2024.2371575.


References
1.
Luo P, Yin P, Hua R, Tan Y, Li Z, Qiu G . A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology. 2017; 67(2):662-675. PMC: 6680350. DOI: 10.1002/hep.29561. View

2.
Cai J, Chen L, Zhang Z, Zhang X, Lu X, Liu W . Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019; 68(12):2195-2205. PMC: 6872444. DOI: 10.1136/gutjnl-2019-318882. View

3.
Wang Y, Zhou N, Liu H, Gong X, Zhu R, Li X . Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression. Cancer Med. 2020; 9(14):5086-5094. PMC: 7367640. DOI: 10.1002/cam4.3150. View

4.
Finotello F, Rieder D, Hackl H, Trajanoski Z . Next-generation computational tools for interrogating cancer immunity. Nat Rev Genet. 2019; 20(12):724-746. DOI: 10.1038/s41576-019-0166-7. View

5.
Fridman W, Zitvogel L, Sautes-Fridman C, Kroemer G . The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017; 14(12):717-734. DOI: 10.1038/nrclinonc.2017.101. View